trending Market Intelligence /marketintelligence/en/news-insights/trending/3DH-b3NBCx9aWTDfGkGHAg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Sun Pharmaceutical's US unit wins injunctive relief on Biofrontera dispute

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Sun Pharmaceutical's US unit wins injunctive relief on Biofrontera dispute

Mumbai-based Sun Pharmaceutical Industries Ltd. said the U.S. District Court for the District of Massachusetts has prohibited Biofrontera AG and certain units of the company from using its subsidiary's trade secret information.

Dusa Pharmaceuticals Inc., a wholly owned subsidiary of Sun Pharmaceutical, had filed a lawsuit against the German biotech's units, alleging that the Biofrontera companies infringed on its patents for its topical medication, Levulan Kerastick, and the specific wavelength light emitter, Blu-U Blue Light, used in photodynamic therapy.

Photodynamic therapy treats minimally to moderately thick actinic keratosis of the face or scalp. Actinic keratosis is a common skin condition caused by sun damage and characterized by scaly patches on the skin that could progress to skin cancer.

The court issued a preliminary injunction order, finding that "Biofrontera by its own admission is in possession of at least 600 DUSA documents obtained from 20+ employees that have left DUSA for Biofrontera in recent years," "that these documents contain confidential and proprietary information," and "that Biofrontera has competed against DUSA unfairly exploiting know-how that took DUSA years to develop," the Sun Pharma unit said in a news release.

Biofrontera cannot use any of DUSA Pharmaceuticals' confidential and proprietary trade secret information to sell and market its own photodynamic therapy products, Amleuz and BF-RhodoLED, until the federal court makes a final determination in the legal case.

The court stated that "at this early stage, it would appear that DUSA has a reasonable prospect of success on the merits," DUSA Pharmaceuticals said.